Rashmi Verma, M.D.
Assistant Health Science Clinical Professor
To see if Rashmi Verma is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Specialties
Oncology
Genitorurinary
Gastrointestinal Medicine
Hematology/Oncology
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Philosophy of Care
Dr. Rashmi Verma is an adult medical oncologist who specializes in medical treatment of Gastrointestinal and Genitourinary malignancies including esophageal, gastric, pancreatic, liver, gall bladder, cholangiocarcinoma, colorectal and anal cancers, kidney, bladder, prostate and testicular cancers.
She is a strong advocate for patients and believes in treating not only the medical condition but patient in total.
Each patient requires a varied amount of physical, emotional, psychological, and social support. She believes that patient has equal right in making decisions regarding treatment options.
Dr. Rashmi Verma believes in providing comprehensive care to patients such as options for immuno-oncology, mutational profiling, molecular targeted therapies, regional therapies, clinical trials and supportive care.
She believes that positive thinking besides novel treatment strategy is best therapy!
Clinical Interests
Dr. Rashmi Verma is an adult medical oncologist who specializes in medical treatment of Gastrointestinal and Genitourinary malignancies including esophageal, gastric, pancreatic, liver, gall bladder, cholangiocarcinoma, colorectal and anal cancers, kidney, bladder, prostate and testicular cancers.
Research/Academic Interests
Dr. Rashmi Verma is interested in conducting clinical trials for these malignancies and has interest in novel treatments for Gastrointestinal and Genitourinary cancer including targeted therapies, immunotherapies.
Also, she is interested and involved in clinical education of medical students, residents and fellows. She also volunteers at UC Davis medical student run community clinics.
Division
Hematology and Oncology
Center/Program Affiliation
Medical School
M.B.B.S., University College of Medical Sciences, Delhi University, Delhi, India 1994
Internship
Internal Medicine (PGY1-2), University of South Dakota and VA Hospital, Sioux Falls SD 2009-2011
Residency
Internal Medicine (PGY3), University of Medicine and Dentistry of New Jersey and Cooper University Hospital, Camden NJ 2011-2012
Fellowship
Hematology & Oncology, Texas Tech University, Lubbock TX 2013-2016
Chief Fellow during Hematology & Oncology Fellowship,
Fellow of American College of Physicians,
Verma R. Neoadjuvant Cabozantinib in Renal Cell Carcinoma: A Case Series and Review of Literature. Clin Genitourinary J. 2020 April.
Mirandola L, Wade R, Verma R, Pena C, Hosiriluck N, Figueroa JA, Cobos E, Jenkins MR, Chiriva-Internati M. Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol. 2015 Mar;34(2):134-42. doi:10.3109/08830185.2015.1018417. PMID:25901858.
Lu C, Figueroa JA, Liu Z, Konala V, Aulakh A, Verma R, Cobos E, Chiriva-Internati M, Gao W. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection. Curr Cancer Drug Targets. 2015;15(7):575-92. doi:10.2174/156800961507150828223554. PMID:26324128.
Cobos E, Figueroa J, Mirandola L, Verma R. International Reviews of Immunology: co-author: The Role of Human Papilloma Virus (HPV) Infection in Non- Anogenital cancer and the Promise of Immunotherapy: A Review. International Reviews of Immunology. 2014;33(5).
Riaz J, Verma R, et al. Cancer testis antigens: Potential new targets for lung cancer. MirandolaL. J Clin Oncology. 2014;32:15.
Riaz J, Verma R, Mirandola L, et al. Effect of the novel galectin-3 blocker, Gal3M, on the efficacy and reduction of toxicity of proteasome inhibitors for the treatment of multiple myeloma. J Clin Oncology. 2014;32:15 SUPPL 1.
Verma R, Riaz J, et al. Effect of galectin-3 inhibition on drug resistance, motility, invasion, and angiogenic potential in ovarian cancer. J Clin Oncology. 2014;32:15 SUPPL 1.
Lynch DW, Verma R, Larson E, Geis MC, Jassim AD. Primary cutaneous mantle cell lymphoma with blastic features: report of a rare case with special reference to staging and effectiveness of chemotherapy. J Cutan Pathol. 2012 Apr;39(4):449-53. doi:10.1111/j.1600-0560.2011.01832.x. Epub 2011 Nov 29. PMID:22121909.
Gupta BK, Maher DM, Ebeling M, Verma R, et al. MUC13 expression enhances colon cancer progression. Cancer Research. 2011;71:8 SUPPL 1.